Wednesday - December 05, 2018 Bayer to drive value creation as company pursues ambitious growth targets through 2022 Company strongly positioned to benefit from key megatrends / Through 2022, Bayer aims to grow sales by 4 percent, EBITDA before special items by 9 percent and free cash flow by 18 percent annually on average / Adjusted EBITDA margin targets for 2022: Crop Science to exceed 30 percent, Pharmaceuticals to hit more than 35 percent, and Consumer Health to reach approximately 24 percent more
Wednesday - October 24, 2018 2018 winners of the Global Ophthalmology Award Programme announced Out of more than 100 submissions, 12 ophthalmology researchers and clinicians will receive awards of up to $50,000 to support their innovative research as part of the 2018 Global Ophthalmology Awards ProgrammeJasmina Kapetanovic from the University of Oxford receives Fellowship Award more
Friday - September 28, 2018 Protecting patient access to licensed and NICE recommended treatments for wet age-related macular degeneration Following the judicial review judgment on 21 September, the High Court has decided that in certain circumstances it is lawful to offer patients bevacizumab injections for the treatment of wet age-related macular degeneration (wet AMD) in preference to approved licensed treatments, even though bevacizumab is not manufactured or licensed for use in the eye. more
Advancing Together: Bayer to Acquire Monsanto The acquisition realizes the joint vision of integrated agricultural offering delivering superior solutions for growers and creates an innovation powerhouse for the next generation of farming. more
